Abstract

Abstract A group of cyclooxygenase‐2 (COX‐2)‐specific fluorescent cancer biomarkers were synthesized by linking the anti‐inflammatory drugs ibuprofen, ( S )‐naproxen, and celecoxib to the 7‐nitrobenzofurazan (NBD) fluorophore. In vitro COX‐1/COX‐2 inhibition studies indicated that all of these fluorescent conjugates are COX‐2 inhibitors (IC 50 range: 0.19–23.0 μ M ) with an appreciable COX‐2 selectivity index (SI≥4.3–444). In this study the celecoxib–NBD conjugate N ‐(2‐((7‐nitrobenzo[ c ][1,2,5]oxadiazol‐4‐yl)amino)ethyl)‐4‐(5‐( p ‐tolyl)‐3‐(trifluoromethyl)‐1 H ‐pyrazol‐1‐yl)benzenesulfonamide ( 14 ), which displayed the highest COX‐2 inhibitory potency and selectivity (COX‐2 IC 50 =0.19 μ M ; SI=443.6), was identified as an impending COX‐2‐specific biomarker for the fluorescence imaging of cancer using a COX‐2‐expressing human colon cancer cell line (HCA‐7).

Keywords

CyclooxygenaseChemistryCelecoxibFluorophoreConjugateNaproxenIn vitroEnzymeCancerEtodolacFluorescencePharmacologyBiochemistryStereochemistryMedicinePathologyInternal medicine

Affiliated Institutions

Related Publications

Publication Info

Year
2013
Type
article
Volume
9
Issue
1
Pages
109-116
Citations
42
Access
Closed

External Links

Citation Metrics

42
OpenAlex

Cite This

Atul Bhardwaj, Jatinder Kaur, Frank Wuest et al. (2013). Fluorophore‐Labeled Cyclooxygenase‐2 Inhibitors for the Imaging of Cyclooxygenase‐2 Overexpression in Cancer: Synthesis and Biological Studies. ChemMedChem , 9 (1) , 109-116. https://doi.org/10.1002/cmdc.201300355

Identifiers

DOI
10.1002/cmdc.201300355